Title: Study on Clinical Characteristics and Related Factors of Schizophrenia Patients with
Intestinal Obstruction Running title: Schizophrenia with Intestinal Obstruction
Version: 1 Date: 18 Oct 2021
Reviewer:  Valentin Matei
Reviewer's report:
In the background the authors failed to offer the readers information about intestinal obstruction
in normal population (which would be very important in order to understand if the risk are
different between schizophrenia patients and controls.  Also there is not a proper presentation
of the data regarding intestinal obstruction in schizophrenia patients (instead authors stated
bluntly that “there are still few studies on the clinical characteristics and related risk factors of
schizophrenia patients with intestinal obstruction” without citing any of papers of interest for
the topic at hand.
One of the most important risk factors for intestinal obstruction in schizophrenia patients is
medication (an especially clozapine use Susanna Every-Palmer, Mike Nowitz, James Stanley,
Eve Grant, Mark Huthwaite, Helen Dunn, Pete M. Ellis, Clozapine-treated Patients Have
Marked Gastrointestinal Hypomotility, the Probable Basis of Life-threatening Gastrointestinal
Complications: A Cross Sectional Study, EBioMedicine,
Volume 5, 2016, Pages 125-134). The authors didn’t analyze at all the putative role of
treatment even though they acknowledged the importance of treatment as risk factor for
intestinal obstruction in discussion part: “5) The anticholinergic effect of drugs for the treatment
of schizophrenia can inhibit the contraction of gastrointestinal smooth muscle and reduce
gastrointestinal secretion and peristalsis. Therefore, the longer the course of the disease, the
longer the medication time, and the greater the dosage, the more frequent the patient’s intestinal
obstruction.”
Title: Study on Clinical Characteristics and Related Factors of Schizophrenia Patients with
Intestinal Obstruction Running title: Schizophrenia with Intestinal Obstruction
Version: 1 Date: 18 Oct 2021
Reviewer:  Valentin Matei
Reviewer's report:
In the background the authors failed to offer the readers information about intestinal obstruction
in normal population (which would be very important in order to understand if the risk are
different between schizophrenia patients and controls.  Also there is not a proper presentation
of the data regarding intestinal obstruction in schizophrenia patients (instead authors stated
bluntly that “there are still few studies on the clinical characteristics and related risk factors of
schizophrenia patients with intestinal obstruction” without citing any of papers of interest for
the topic at hand.
One of the most important risk factors for intestinal obstruction in schizophrenia patients is
medication (an especially clozapine use Susanna Every-Palmer, Mike Nowitz, James Stanley,
Eve Grant, Mark Huthwaite, Helen Dunn, Pete M. Ellis, Clozapine-treated Patients Have
Marked Gastrointestinal Hypomotility, the Probable Basis of Life-threatening Gastrointestinal
Complications: A Cross Sectional Study, EBioMedicine,
Volume 5, 2016, Pages 125-134). The authors didn’t analyze at all the putative role of
treatment even though they acknowledged the importance of treatment as risk factor for
intestinal obstruction in discussion part: “5) The anticholinergic effect of drugs for the treatment
of schizophrenia can inhibit the contraction of gastrointestinal smooth muscle and reduce
gastrointestinal secretion and peristalsis. Therefore, the longer the course of the disease, the
longer the medication time, and the greater the dosage, the more frequent the patient’s intestinal
obstruction.”
Please review this paper.
user
Title: Study on Clinical Characteristics and Related Factors of Schizophrenia Patients with
Intestinal Obstruction Running title: Schizophrenia with Intestinal Obstruction
Version: 1 Date: 18 Oct 2021
Reviewer:  Valentin Matei
Reviewer's report:
In the background the authors failed to offer the readers information about intestinal obstruction
in normal population (which would be very important in order to understand if the risk are
different between schizophrenia patients and controls.  Also there is not a proper presentation
of the data regarding intestinal obstruction in schizophrenia patients (instead authors stated
bluntly that “there are still few studies on the clinical characteristics and related risk factors of
schizophrenia patients with intestinal obstruction” without citing any of papers of interest for
the topic at hand.
One of the most important risk factors for intestinal obstruction in schizophrenia patients is
medication (an especially clozapine use Susanna Every-Palmer, Mike Nowitz, James Stanley,
Eve Grant, Mark Huthwaite, Helen Dunn, Pete M. Ellis, Clozapine-treated Patients Have
Marked Gastrointestinal Hypomotility, the Probable Basis of Life-threatening Gastrointestinal
Complications: A Cross Sectional Study, EBioMedicine,
Volume 5, 2016, Pages 125-134). The authors didn’t analyze at all the putative role of
treatment even though they acknowledged the importance of treatment as risk factor for
intestinal obstruction in discussion part: “5) The anticholinergic effect of drugs for the treatment
of schizophrenia can inhibit the contraction of gastrointestinal smooth muscle and reduce
gastrointestinal secretion and peristalsis. Therefore, the longer the course of the disease, the
longer the medication time, and the greater the dosage, the more frequent the patient’s intestinal
obstruction.”
assistant